In the Specification

Please replace the paragraph beginning on page 1, line 5, with the following rewritten paragraph.

--This application is a continuation-in-part of U.S.S.N. 09/536,087, filed March 24, 2000, which claims priority to U.S.S.N. 60/127,221, filed March 31, 1999. This application is also a continuation-in-part of U.S.S.N. 09/770,339, filed January 26, 2001, which claims priority to U.S.S.N. 60/178,842, filed January 27, 2000.--

In The Claims

Please amend the following claims:

1. (Amended) A method for treating a disorder characterized by excessive proliferation of tissue comprising implanting a cell-matrix structure in an amount sufficient to stop or regress the excessive tissue proliferation, wherein said cell-matrix structure comprises a matrix having attached thereto cells stably expressing a gene encoding an anti-angiogenic molecule.

5. (Amended) The method of claim 1 wherein the cells are genetically engineered to produce the anti-angiogenic molecule.

6. (Amended) The method of claim 1 wherein the anti-angiogenic molecule is thrombomodulin.

Please add the following claims:

--16. (New) A method for treating a disorder characterized by excessive proliferation of tissue comprising implanting a cell-matrix structure in an amount sufficient to stop or regress the excessive tissue proliferation, wherein said cell-matrix structure comprises a matrix having attached thereto cells stably expressing a gene encoding a thrombospondin-2 (TSP-2).

17. (New) The method of claim 16, wherein the disorder is selected from the group consisting of malignant and benign neoplasias, vascular, inflammatory conditions causing excessive proliferation of cells, keloid formation, intraperitoneal or intrathoracic adhesions, endometriosis, congenital or endocrine abnormalities, psoriasis, unwanted skin proliferation, rheumatoid arthritis, multiple sclerosis, unwanted angiogenesis of the eye, restenosis, and infections causing excessive proliferation of cells.